4883.T
Modalis Therapeutics Corporation
グロース · 医薬品 · 医薬品 · JP
JPY 35.00
+2.94%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -29.9%
- EPS
- +23.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -65.4%
- Net income
- -63.4%
- EPS
- +2.5%
- Free cash flow
- -48.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026